跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/CTRI/2017/08/009356
CTRI/2017/08/009356进行中（未招募）未知

A multicenter, open label, randomized, balanced, steady state, two treatment, two period, two sequence, two-way crossover, multiple dose, bioequivalence study of Imatinib Mesylate Tablet 400 mg of Natco Pharma Limited, India with Gleevec® (Imatinib Mesylate) Tablet 400 mg of Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936 in adult human patients with Chronic Myeloid Leukemia and/or Gastrointestinal Stromal Tumor stabilized on Imatinib Mesylate 400 mg under fed condition.

atco Pharma Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
未知
状态
进行中（未招募）
发起方
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Ba/be

入排标准

入选标准

  • •1.Men and women, of age in between 18 years to 65 years (both inclusive).
  • •2.Ability to provide written informed consent prior to participation in the study.
  • •3.Chronic phase Chronic Myeloid Leukemia (CML) patients with documented evidence of Philadelphia positive chromosome who are on stable dose regimen of 400 mg once daily dose of Imatinib.
  • •Kit (CD 117) positive Gastrointestinal Stromal Tumor (GIST) (with documented evidence), who are on a stable dose regimen of 400 mg once daily dose of Imatinib.
  • •4.Adequate organ function, defined as the following:
  • •Hemoglobin > 9 mg/dL
  • •Total bilirubin < 1.5 x upper limit of normal (ULN)
  • •SGOT and SGPT < 2.5 x ULN
  • •Serum Creatinine < 1.5 x ULN
  • •Absolute neutrophil count (ANC) >=1.5 x 109/L
  • •Platelets >= 100 x 109/L
  • •HbA1c < 9 %
  • •5.Females of child-bearing potential (FOCP) must have negative pregnancy test at screening and must agree to use an acceptable method of birth control such as sexual abstinence or at least 2 reliable modes of contraception, one of which must be a double-barrier method (e.g., condom with spermicidal gel or diaphragm with spermicidal gel) or IUD or vaginal spermicidal suppository from screening until 14 days after last dose of study drug. [Note: Use of hormonal contraception (pills/hormonal intrauterine device etc,) is not allowed.] Patient agrees to accept the risk that pregnancy could still result despite using birth control devices.
  • •Post-menopausal females defined as 12 consecutive months of amenorrhea.
  • •Surgically sterilized females with documented evidence of hysterectomy / bilateral salpingectomy / bilateral oophorectomy. Females without documented evidence of surgery and those who has undergone tubal ligation will be considered of child bearing potential.
  • •6.Male patient must agree to use an acceptable method of birth control such as sexual abstinence or barrier method of contraception (i.e. condom) from screening until 14 days after last dose of study drug. Patient agrees to accept the risk that pregnancy in female partner could still result despite using birth control devices.
  • •7.No history of participation in any clinical study within the past 90 days.

排除标准

  • •1.Patients in accelerated phase or blast crisis phase.
  • •2.Patients for whom a titration away from 400 mg dose is likely during the entire study period as per Investigatorâ??s judgement.
  • •3.Patient received any treatment for CML prior to study entry for longer than 2 weeks with the exception of hydroxyurea and/or anagrelide and/or imatinib.
  • •4.History of patient with another primary malignancy except if the other primary malignancy is neither currently clinically significant or requiring active intervention.
  • •5.Patient having history of major surgery within 4 weeks prior to study entry, or who have not recovered from prior major surgery.
  • •6.Patients with an ECOG (Eastern Cooperative Oncology group) Performance Status Score > 3.
  • •7.Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent.
  • •8.Patients with identified sibling donors where allogeneic bone marrow transplant is elected as first line treatment.
  • •9.Patients who are on or may require concomitant medications which are known to be inhibitors and/or inducers of CYP3A4 family (Annexure IV).
  • •10.History of hematopoietic stem cell transplantation.
  • •11.History of hypersensitivity to Imatinib or any of its excipients or related group of drugs.
  • •12.Patients who are eligible and willing to undergo transplantation during the entire study period.
  • •13.History of patients taking certain medications that are accepted to have a risk of causing Torsades de Pointes.
  • •14.History of patients taking medications that irreversibly inhibit platelet function or anticoagulants.
  • •15.History of uncontrolled diseases, such as thyroidal dysfunction, diabetes mellitus, angina pectoris, heart failure, neuropsychiatric disorders.
  • •16.Patients who are at clinically high risk of developing Tumor Lysis Syndrome as per the investigatorâ??s evaluation.
  • •17.Patients who have undergone thyroidectomy or patients receiving levothyroxine.
  • •18.Patients with history of bullous dermatologic reactions, including erythema multiforme and Stevens-Johnson syndrome during the prior therapy with imatinib or any other drug.
  • •19.Recent history (within 6 months) of alcohol and/or drug addiction.
  • •20.Patients who are human immunodeficiency virus (HIV) and HbsAg positive.
  • •21.History of ascites and rapid weight gain with or without superficial edema.
  • •22.History of prior radiotherapy to bone marrow.
  • •23.Use of other concurrent anticancer agents other than Imatinib, including chemotherapy or biologic agents.
  • •24.Positive results for drugs of abuse (benzodiazepines, opioids, amphetamines, cannabinoids cocaine and barbiturates) in urine.
  • •25.Positive results for alcohol as detected by Alcohol Breath Analyzer.
  • •26.History of difficulty with donating blood or difficulty in accessibility of veins.
  • •27.An unusual or abnormal diet, for whatever reason e.g. religious fasting.
  • •28.High caffeine (more than 5 cups of coffee or tea/day) or tobacco (more than 9 cigarettes/ beedies/ cigars per day) consumption.
  • •29.History of patient for whom oral administration of drug is not possible.
  • •30.Any other condition or abnormal baseline findings that, in the investigatorâ??s judgment, might increase the risk to the patient or decrease the chance of obtaining satisfactory data ne

研究者

发起方
atco Pharma Limited

相似试验

已完成
不适用
Comparative study for Imatinib Mesylate 400mg tablets of Sponsor with Imatinib Mesylate 400mg tablets of (Gleevec®)Novartis Pharmaceuticals Corporation, New Jersey in patients with Chronic Myeloid Leukemia and/or Gastrointestinal Stromal Tumor under fed steady-state condition.
CTRI/2015/02/005508Dr Reddys Laboratories Limited32
进行中（未招募）
2 期
Bioequivalence study of Ferric carboxymaltose solution in patients with iron deficiency anemia.
CTRI/2024/02/062551DifGen Pharmaceuticals LLC,
已完成
不适用
Two-treatment bioequivalence study of Ferric carboxymaltose solution injection/infusion (50 mg iron/mL) in patients with iron deficiency anemia.
CTRI/2022/10/046637Dr. Reddy’s Laboratories Ltd.155
招募中
不适用
Bioequivalence study of Ferric carboxymaltose solution in patients with irondeficiency anemia, for whom oral iron preparations are ineffective or cannot beused, under fasting condition.
CTRI/2021/08/035672Dr Reddys Laboratories Ltd
已完成
不适用
A multicenter, open label study of hydroxyurea capsules in sickle cell anemia patients already on stable regimens of hydroxyurea,
CTRI/2022/03/041280Qilu Pharmaceutical Co Ltd32